Archives
-
Grazoprevir/Elbasvir: Evidence for HCV Therapy
2026-10-07
The reference paper presents grazoprevir/elbasvir as a complementary, interferon-free direct-acting antiviral combination that blocks HCV replication at the NS3/4A protease and NS5A replication-complex levels. Its main contribution is a clinically oriented synthesis of efficacy, tolerability, resistance, and special-population evidence, while also defining the limits of applying trial findings across genotypes and comorbidities.
-
Zika Virus Phosphoproteome Maps Host Regulation
2026-10-07
A 2026 PLOS Pathogens study created a global mass-spectrometry map of host-driven post-translational modifications across eight Zika virus proteins. The work links envelope-protein phosphorylation with viral particle release and cytopathogenicity, while identifying host kinase interactions and Bosutinib-sensitive regulation as important directions for antiviral research.
-
CMC Lessons for Translating mRNA Lipid Nanoparticles
2026-10-06
Liu and colleagues present a CMC-centered framework for translating mRNA lipid nanoparticles, connecting lipid chemistry, manufacturing choices, critical quality attributes, analytical characterization, and scale-change comparability. The review’s main contribution is organizational and translational rather than a new formulation: it shows why delivery performance must be evaluated together with manufacturability, stability, impurity control, and regulatory evidence.
-
Cy3 TSA Fluorescence System Kit for Astrocyte Mapping
2026-10-05
The Cy3 TSA Fluorescence System Kit can provide a conceptual bridge between astrocyte transcriptomic atlases and spatial fluorescence microscopy detection. This article examines how tyramide amplification may support orthogonal validation while distinguishing molecular localization from quantitative expression.
-
PD0325901: MEK Inhibition in Cancer Research
2026-10-05
This source-grounded overview examines PD0325901 as a research tool for studying MEK–ERK signaling, reported effects on proliferation and tumor models, and the relevance—but not direct applicability—of recent single-molecule chromatin research. It distinguishes supplier-reported findings from published evidence and outlines key limitations without providing experimental procedures.
-
Multiple Myeloma Cell Lines: Mutation and Drug Response
2026-10-04
A 2019 Theranostics study used whole-exome sequencing across 30 human multiple myeloma cell lines to define recurrent mutations, altered pathways, and links between genotype and drug response. Its main contribution is a molecular reference framework for selecting cell-line models, while its findings remain associative and require validation in primary tumors and relevant microenvironmental systems.
-
APEX2 Supports TERT Expression in Human Stem Cells
2026-10-01
A bioRxiv preprint reports that APEX2, but not its paralog APEX1, is required for efficient TERT expression and telomerase activity in human embryonic stem cells and a melanoma cell line. RNA-seq and chromatin immunoprecipitation connect this effect to APEX2 association with repetitive MIR and Alu-rich DNA, suggesting that DNA repair at TERT-associated repeats may influence gene expression.
-
Gepotidacin–Gyrase Mechanism in S. aureus
2026-10-01
The reference study defines how gepotidacin inhibits Staphylococcus aureus gyrase through a cleavage pattern that differs fundamentally from that of fluoroquinolones. Biochemical assays and crystal structures show selective stabilization of single-stranded DNA breaks, providing a mechanistic framework for developing antibacterial agents that can retain activity against fluoroquinolone-resistant bacteria.
-
Perospirone (SM-9018 freebase) Assay Guide
2026-10-01
A scenario-driven guide to using Perospirone (SM-9018 freebase), SKU BA5009, in viability, proliferation, receptor-mechanism, and vascular electrophysiology workflows. It addresses solvent compatibility, assay interpretation, storage, and vendor-selection decisions using product specifications and peer-reviewed Kv-channel data.
-
AZD3463: ALK/IGF1R Inhibitor Workflow
2026-09-30
AZD3463 provides a practical way to interrogate ALK- and IGF1R-dependent signaling, apoptosis, autophagy, and chemotherapy response in neuroblastoma models. This workflow combines genotype-aware dosing, pathway-resolved readouts, and reproducibility principles adapted from a chemically defined stem-cell differentiation study.
-
BAPTA for Calcium Signaling and Apoptosis
2026-09-29
BAPTA provides a practical way to test whether free Ca2+ is a causal signal rather than a downstream marker in toxicology, apoptosis, and cell signaling studies. This guide translates a nanoplastic–cadmium intestinal-cell model into reproducible preparation, dosing, control, and troubleshooting workflows.
-
CXCR4 Theranostics in Lymphoma: Imaging to Therapy
2026-09-29
The 2026 review by Dhamecha and colleagues presents CXCR4 as a receptor-level bridge between lymphoma imaging, prognostic assessment, and targeted treatment. It organizes peptide radiotracers, small molecules, radioligand therapies, and antibodies into a theranostic framework while emphasizing physiological off-target uptake and CXCR7 compensation as major translational limitations.
-
Marein Reverses ABCG2-Mediated Drug Resistance
2026-09-28
A 2024 Biochemical Pharmacology study identifies marein, a flavonoid from Coreopsis tinctoria, as a competitive inhibitor of the ABCG2 drug-efflux transporter. By increasing intracellular levels of ABCG2 substrates—including mitoxantrone, topotecan, and olaparib—the study provides a mechanistic framework for restoring chemosensitivity in transporter-overexpressing cancer cells.
-
METTL16–SENP3–LTF and Ferroptosis Resistance in HCC
2026-09-28
Wang et al. identify a METTL16–SENP3–LTF pathway that lowers the labile iron pool and helps hepatocellular carcinoma cells resist ferroptosis. Their multi-model evidence connects m6A-dependent regulation of SENP3 to LTF stability and tumor progression, highlighting an iron-metabolism mechanism for further study rather than validating a particular iron chelator as a treatment.
-
ATRX Loss Sensitizes High-Grade Glioma to RTK Inhibitors
2026-09-27
A preclinical study found that ATRX-deficient high-grade glioma cells were more sensitive to several receptor tyrosine kinase and PDGFR inhibitors than ATRX-proficient comparators. The results also point to a potential benefit from combining RTK inhibition with temozolomide, while underscoring the need to evaluate ATRX status in relevant clinical-trial analyses.